Table 1.
Baseline patient characteristics of cohort (n = 20).
| Subcategories | Baseline ctDNA Low * MAF < 1% (n = 8) |
Baseline ctDNA High MAF ≥ 1% (n = 7) |
Tissue/Plasma Neg. (n = 5) |
Total (n = 20) |
|---|---|---|---|---|
| Age | 70 (67–78) | 70 (59–76) | 70 (68–75) | 71 (67–76) |
| Gender | ||||
| Male | 5 (62.5) | 5 (71.4) | 3 (60) | 13 (65) |
| Female | 3 (37.5) | 2 (28.6) | 2 (40) | 7 (35) |
| ECOG | ||||
| 0 | 7 (87.5) | 3 (42.8) | 4 (80) | 14 (70) |
| 1 | 1 (12.5) | 2 (28.6) | 0 (0) | 3 (15) |
| 2 | 0 (0) | 1 (14.3) | 0 (0) | 1 (5) |
| Unknown | 0 (0) | 1 (14.3) | 1 (20) | 2 (10) |
| Melanoma Type | ||||
| Cutaneous melanoma | 8 (100) | 4 (57.1) | 3 (60) | 15 (75) |
| Uveal melanoma | 0 (0) | 0 (0) | 1 (10) | 1 (5) |
| Mucosal melanoma | 0 (0) | 1 (14.3) | 0 (0) | 1 (5) |
| Unknown primary | 0 (0) | 2 (28.6) | 1 (20) | 3 (15) |
| Tissue localization | ||||
| Primary | 4 (50) | 4 (57.1) | 2 (40) | 10 (50) |
| Metastasis | 4 (50) | 3 (42.9) | 2 (40) | 9 (45) |
| Missing | 0 (0) | 0 (0) | 1 (20) | 1 (5) |
| Tissue mutation | ||||
| BRAF | 5 (62.5) | 5 (71.4) | 0 (0) | 10 (50) |
| NRAS | 2 (25) | 1(14.3) | 0 (0) | 3 (15) |
| CDKN2A | 1 (12.5) | 0 (0) | 0 (0) | 1 (5) |
| GNAQ | 0 (0) | 1 (14.3) | 0 (0) | 1 (5) |
| neg. | 0 (0) | 0 (0) | 5 (100) | 5 (25) |
| AJCC tumor stage | ||||
| IIIC/IIID | 1 (12.5) | 1 (14.3) | 0 (0) | 2 (10) |
| IV | 7 (87.5) | 6 (85.7) | 5 (100) | 18 (90) |
| pT | ||||
| T0 | 1 (12.5) | 0 (0) | 0 (0) | 1 (5) |
| pT1 | 0 (0) | 1 (14.3) | 0 (0) | 1 (5) |
| pT2 | 3 (37.5) | 2 (28.6) | 0 (0) | 5 (25) |
| pT3 | 1 (12.5) | 1 (14.3) | 2 (40) | 4 (20) |
| pT4 | 3 (37.5) | 1 (14.3) | 1 (20) | 5 (25) |
| pTX/Missing | 0 (0) | 2 (28.6) | 2 (40) | 4 (20) |
| pN | ||||
| N0 | 4 (50) | 2 (28.6) | 1 (20) | 7 (35) |
| N1 | 1 (12.5) | 2 (28.6) | 3 (60) | 6 (30) |
| N2 | 3 (37.5) | 0 (0) | 1 (20) | 4 (20) |
| N3 | 0 (0) | 3 (42.8) | 0 (0) | 3 (15) |
| M stage | ||||
| M0 | 1 (12.5) | 1 (14.3) | 0 (0) | 2 (10) |
| M1a | 0 (0) | 1 (14.3) | 0 (0) | 1 (5) |
| M1b | 5 (62.5) | 1 (14.3) | 2 (40) | 8 (40) |
| M1c | 2 (25) | 2 (28.6) | 3 (60) | 7 (35) |
| M1d | 0 (0) | 2 (28.6) | 0 (0) | 2 (10) |
| Number of metastatic sites | ||||
| 1 | 3 (37.5) | 2 (28.6) | 2 (40) | 7 (35) |
| 2 | 4 (50) | 3 (42.8) | 1 (20) | 8 (40) |
| ≥3 | 1 (12.5) | 2 (28.6) | 2 (40) | 5 (25) |
| S100 | ||||
| ≤1× ULN | 8 (100) | 0 (0) | 3 (60) | 11 (55) |
| >1× ULN | 0 (0) | 7 (100) | 2 (40) | 9 (45) |
| LDH | ||||
| ≤1× ULN | 7 (87.5) | 3 (42.9) | 0 (0) | 10 (50) |
| >1× ULN | 1 (12.5) | 4 (57.1) | 5 (100) | 10 (50) |
| Treatment type | ||||
| Targeted therapy | 2 (25) | 3 (42.9) | 0 (0) | 5 (25) |
| Immunotherapy | 6 (75) | 4 (57.1) | 5 (100) | 15 (75) |
Data are presented as median (IQR) for continuous variables as age and absolute frequencies (%) for categorical variables. IQR, interquartile range; MAF, mutant allele frequency; ULN, upper limit of normal; LDH, lactate dehydrogenase. * Includes 5 patients with undetectable ctDNA (MAF = 0%) at baseline.